Locations:

Multiple Sclerosis

July 1, 2021/Neurosciences/Multiple Sclerosis

Deep Gray Matter Injury in Multiple Sclerosis: What We Know, Why It Matters

A new NAIMS consensus statement summarizes evidence, guides MRI investigation

21-NEU-2079842_COVID-19-in-MS-patients_650x450

March 29, 2021/COVID-19

Registry Study Pinpoints Risk Factors for Worse COVID-19 Outcomes in Patients With MS

Ambulation disability carries greatest risk, most disease-modifying therapies aren’t implicated

March 9, 2021/Genomic Medicine

Learning from Multiple Sclerosis Misdiagnosis: Insights Into Genetic Leukodystrophies

Clinical cohort study helps define red flags for these rare MS mimics

21-NEU-2050870_woman-in-wheelchair_650x450

February 15, 2021/Neurosciences/Multiple Sclerosis

How Do Patients With Multiple Sclerosis Perceive the U.S. Drug Approval Process?

Survey suggests need for education about FDA’s mission, trustworthiness

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

21-NEU-2046760_CQD_650x450_200158799_with mask

February 11, 2021/Neurosciences/Multiple Sclerosis

In Patients With NMOSD, Early Age at Onset Is Associated With Severity of Visual Loss

Large cohort study supports early consideration of aggressive therapy

December 31, 2020/Neurosciences/Multiple Sclerosis

Cannabis Extract Improves Spasticity Without Increasing Weakness in Patients With MS

Cannabinoid oromucosal spray is poised for FDA submission in 2021

BackPage 6 of 6Next